Stay updated on Proviral Genotype-Guided ART Clinical Trial
Sign up to get notified when there's something new on the Proviral Genotype-Guided ART Clinical Trial page.

Latest updates to the Proviral Genotype-Guided ART Clinical Trial page
- Check7 days agoChange DetectedAdded the ART-PRO publication (Dolutegravir + lamivudine with the 2023 erratum) and removed the earlier 2020 EBioMedicine citation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedFooter updates include adding Revision: v3.3.3 and removing HHS Vulnerability Disclosure and Revision: v3.3.2 from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoNo Change Detected
- Check51 days agoChange DetectedThe Publications section now states that entries are automatically filled from PubMed and may not be about the study. The revision label was updated to v3.3.2 from v3.2.0.SummaryDifference0.1%

- Check58 days agoChange DetectedThe general government funding status notice at the top of the ClinicalTrials.gov page was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check79 days agoChange DetectedNo substantive changes to the study details are present; the page content remains the same with only minor visual layout differences between the screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check101 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference4%

Stay in the know with updates to Proviral Genotype-Guided ART Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Proviral Genotype-Guided ART Clinical Trial page.